AGuIX
- Generic Name
- AGuIX
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates. It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.
- Associated Conditions
- -
- Associated Therapies
- -
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04789486
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 1
- Registration Number
- NCT04094077
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 15
- Registration Number
- NCT02820454
- Locations
- 🇫🇷
University Hospital Grenoble, Grenoble, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath